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Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder in children, with a worldwide cumulative 
prevalence in children of 8-20%. The number of AD patients is beyond the level that can be dealt with at clinics and it is time to make 
an effort to reduce the number of AD patients in the community. Thus, caregivers and all persons involved with AD management, 
including health care providers, educators, technologists and medical policy makers, should understand the development and the 
management of AD. Although a number of guidelines such as Practical Allergy (PRACTALL) report have been developed and used, 
community understanding of these is low. This is probably because there are still remarkable differences in management practices 
between specialists and between countries and most of the reported guidelines have been prepared for physicians. From the 
viewpoint of providing a basis for a multidisciplinary team approach, easily comprehensible guidelines for organizing treatment of AD, 
i.e. an Atopic Dermatitis Organizer (ADO), are required. guidelines should be simple and well organized. We suggest an easy approach 
with a new classification of AD symptoms into early and/or progressive lesions in acute and/or chronic symptoms. The contents of this 
ADO guideline basically consist of 3 steps approaches: conservative management, topical anti-inflammatory therapy, and systemic 
anti-inflammatory therapy.
Key words: Atopic dermatitis; Classification, Management; Guideline
Correspondence: Sang-Il Lee
Department of Pediatrics, Samsung Medical Center, 
50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea
Tel: +82-2-3410-3521
Fax: +82-2-3410-0805
E-mail: childslee@skku.edu
Received: July 1, 2011
Accepted: July 10, 2011  
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution. Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is 
properly cited.
Copyright © 2011. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. 
http://apallergy.org
INTRODUCTION
While atopic dermatitis (AD) has been classified into two 
types depending on its immunoglobulin E (IgE)-mediated 
mechanism, it is generally accepted as one of the major allergic 
diseases, particularly in children, because it shows many of the 
characteristics of allergic diseases such as bronchial asthma (BA) 
and allergic rhinitis (AR). These characteristics include a strong 
familial predisposition, evidence of an IgE-mediated immune 
response, sensitivity to allergens and environmental triggers, and 
like BA and AR, a rapid increase in prevalence since the 1980s. 
However, unlike other allergic diseases, it is commonly observed 
in infants and young children and shows a clear tendency 
to disappear or improve with increasing age. AD also has 
characteristic symptoms of rough and dry skin rather than the 
edematous lesions usually found in other allergic diseases. These  apallergy.org
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similarities and differences are very helpful in providing a direction 
for research and in developing effective management.
This article reviews the epidemiologic characteristics and 
the natural course of AD and proposes a new approach for the 
management of AD to reduce the number of patients in the 
community.
Definition
As the pathogenesis of AD remains unknown, it has been 
named differently in different regions. Until the 1970s in Korea, it 
was considered a temporary skin phenomenon observed during 
early infancy and was called “infantile eczema” or “fetal fever”. The 
European revised nomenclature committee has proposed the term 
atopic eczema/dermatitis syndrome instead of atopic eczema [1].
The definition of the disease, like its name, also varies. Based on 
a comprehensive review of the literature, we suggest that the best 
definition of AD is a chronic relapsing inflammatory skin disease 
found mainly in infants and young children with intensely itchy 
and dry skin.
Epidemiologic characteristics
It is clear that the prevalence of allergic diseases such as AD, BA 
and AR has increased all over the world during the last 30 years 
[2, 3]. Although the prevalence differs by age, region and survey 
method, the cumulative prevalence of AD in children is 8-20% [4] 
and, as demonstrated by an International Study of Asthma and 
Allergies in Childhood (ISAAC) continues to increase. Korean ISAAC 
data from elementary school children aged 6-11 years, reported 
every five years since 1995, have also revealed that the cumulative 
prevalence of AD has increased continuously from 19.7% in 1995 
to 29.2% in 2010. However, this differed markedly from the point 
prevalence: a survey in 2009 using the ISAAC questionnaire 
showed 13.1% prevalence of symptoms in the previous 12 months 
and 8.2% prevalence identified by direct physical examination by 
pediatric allergist [5].
Another epidemiologic characteristic of AD is that it is observed 
primarily during infancy. Kay et al. [6] reported that 45% of all cases 
of AD begin within the first six months after birth, 60% during 
the first year and 85% before five years of age. This tendency 
is also shown in the data collected in Korea. According to the 
data from the Korean National Health Insurance Corporation in 
2008 (Fig. 1), 1.08 million patients (2.24% of the total population) 
were registered as having AD. These patients were diagnosed by 
clinicians: pediatricians, dermatologists, internists, family physicians 
and traditional medicine practitioners. Around 118,000 infants 
aged one year (26.5% of the population of this age group) were 
diagnosed with AD. The rate of diagnosis dramatically reduced 
with increasing age: 11.6%, 9.2%, 4.6%, 2.0% and 1% in those 
aged 3, 5, 10, 20 and 30 years, respectively. Among persons aged 
over 40, the rate was less than 0.7%. These data suggest that AD 
principally develops in infancy.
Natural course
In Korea, there is an old saying that “infantile eczema disappears 
when children stand alone or start to talk”. In the early 1990s, the 
textbook introduced AD as a disease with a very high possibility of 
disappearing at 2-3 years of age [7]. 
Illi et al. [8] reported a prospective birth cohort study performed 
with 1,314 subjects from birth to seven years of age. Of the patients 
with AD that occurred before two years of age, 43.2%, 38.3% and 
18.7% showed complete remission, intermittent symptoms or 
continuous symptoms, respectively, at three years of age [8].
The cumulative prevalence and the point prevalence of AD 
among elementary school children in Seoul, Korea, have been 
reported every five years (Fig. 2) [9]. Both measures of prevalence 
increased continuously but because the one-year point prevalence 
was about half the cumulative prevalence, it was assumed that 
50% of AD resolved in elementary school children.
Pathogenesis and etiology
Many genetic and epidemiologic studies have been performed 
[10-12], and have concluded that AD is caused by multiple 
environmental triggers in susceptible individuals. The Practical 
Fig. 1. Korean data on prevalence of atopic dermatitis by age in 2008. These 
data were provided by the Korean National Health Insurance Corporation. The 
patients were diagnosed by clinicians, including pediatricians, dermatologists, 
internists, family physicians and traditional medicine practitioners.   apallergy.org
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       Allergy (PRACTALL) consensus report also extensively reviewed 
the development of AD [13], but there are still many points that 
are difficult to explain. Why does AD occur principally during 
infancy and why do its frequency and severity decrease with 
increasing age? Why has its prevalence increased sharply since the 
1980s along with that of BA and AR and why does AD in infancy 
frequently progress to BA and AR? Why are there few symptoms of 
edema which are frequently found in BA, AR and urticaria? 
Overall, the development of AD is considered to be 
multifactorial. In short, the mechanisms for the development 
of AD involve complex interactions between susceptibility 
genes, immaturity and/or abnormality in barrier function and 
environmental factors (Fig. 3).
Genetic factors
It is well known that genetic factors are involved in all diseases 
and many genetic factors associated with allergic disease have 
been reported. In particular, evidence of a high correlation 
between AD and family history has been found. A cohort study by 
the authors reported such a finding [14]. When both parents had a 
family history and showed sensitization to allergens in a skin prick 
test, the cumulative prevalence of AD up to one year of age was 
41.7%; when only the mother showed sensitization the rate was 
30.7%. However, the rates of AD in children with only a sensitized 
father and with nonsensitized parents were relatively low, recorded 
as 22.2% and 14.7%, respectively. These data suggest that parental 
atopy, particularly maternal atopy, is significantly associated with 
AD in infants.
Hygiene hypothesis
It has been demonstrated that the prevalence of allergic 
diseases increases in a community with a high socioeconomic 
level. Because the prevalence of AD was inversely proportional to 
Fig. 2. Prevalence of atopic dermatitis (AD) in children aged 6–11 years in 
Seoul between 1995 and 2005. The one-year point prevalence (treatment of 
AD, last 12 months) was about 50% of the cumulative prevalence (diagnosis of 
AD, ever). 
Fig. 3. The multifactorial pathogenesis of atopic dermatitis (AD). The mechanisms for the development of AD involve complex interactions between susceptibil-
ity genes, immaturity and/or abnormality in barrier function and environmental factors. apallergy.org
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the prevalence of bacterial infections such as tuberculosis and its 
incidence rate was relatively low in larger families or rural areas, 
the “hygiene hypothesis” was conceived. This hypothesis proposes 
that exposure to bacteria in early infancy plays a major role in 
setting the direction of immune responses, including whether 
a T helper (Th) 1 (proinflammatory) or Th2 (proallergic) type of 
reaction is dominant [15]. Although the hypothesis has recently 
been questioned with regard to AD [16, 17], it is a reasonable 
concept to explain the rapid increase of allergic diseases during 
the past a few decades.
Environmental factors
Environmental factors resulting from industrialization have been 
studied as possible reasons why the incidence of BA, AR and AD 
has skyrocketed since the 1980s. Air pollution generated by cars, 
energy production and factories, air-conditioning and heating, 
indoor environmental changes, and dietary changes have been 
suggested as factors in the development and aggravation of AD 
[16-18].
Some studies showed that exposure to volatile organic 
compounds (VOCs) found in indoor environments can damage 
the epidermal barrier and enhance adverse reactions to house 
dust mite (HDM) [21, 22]. Air pollutants, such as hydrogen sulfide, 
nitrogen dioxide and formaldehyde, may increase the prevalence 
and severity of AD [19, 23].  The authors’ current survey of the 
residential environment of severe AD patients also revealed that 
particulate matter (PM10), formaldehyde, fungi and bacteria levels 
were high, implying that these could be factors aggravating AD.
Food has also been frequently raised as a factor. Based on the 
literature from the past 10 years, the prevalence of food allergy   
in infants with AD was reported to range from 33% to 63% 
[24]. According to the authors’ study of food-specific IgE in AD 
patients, egg-white-specific IgE was detected in 24.3% of patients 
followed by wheat-, milk-, peanut- and soy-specific IgE in order of 
decreasing frequency (Fig. 4). However, it should be considered 
that the causative foods of AD differ by country, region and culture. 
Because most of causative foods are essential for the growth of 
infants and children, food restrictions should be imposed with 
care.
The skin environment of the lesions plays a key role in the 
incidence of AD. The skin of patients with AD is mostly colonized 
by Staphylococcus aureus, a toxin-producing organism [25]. Toxins 
and superantigens secreted by S. aureus activate high numbers 
of T cells and other immune cells, resulting in an exaggerated 
inflammatory response [13, 25]. The skin of AD patients has 
been found to be deficient in antimicrobial peptides, one of the 
components of the innate response essential for host defense 
against bacteria, fungi and viruses [26, 27]. This abnormality 
of innate immunity may explain the increased susceptibility 
to various skin infections of patients with AD. In addition, skin 
infection is a factor aggravating AD and hindering its treatment.
It has been observed that an increased ceramide level and 
decreased endogenous proteolytic enzymes in skin cause elevated 
transepidermal water loss, which provokes a vicious cycle of 
lesions and abnormal skin barrier function. Studies of a mutation 
of filaggrin, a major protein essential to skin barrier formation, have 
recently been reported [28]. A study demonstrating a correlation 
between the mutation and BA was also reported [29]. It was 
suggested that elevated production of the stratum corneum 
chymotryptic enzyme protease led to the breakdown of the 
skin barrier [29]. Soaps and detergents can increase skin pH and 
strengthen the activity of proteases from dust mites or S. aureus, 
thus contributing to epithelial damage.
Immaturity or abnormality of defense mechanisms
Although the prevalence of AD has increased greatly compared 
with the past, its tendency to occur most frequently among 
infants aged one year or less and to reduce with increasing age 
has been maintained. Therefore, while the incidence of AD is 
greatly affected by changes in the environment, overall physical 
immaturity is expected to be an important factor influencing this 
incidence.
In summary, immaturity of skin barrier function, mucosal 
immunity, systemic immunity and digestive enzymes are 
considered to be factors that influence the development of AD 
symptoms in infancy.
Fig. 4. Food sensitization rates in patients with atopic dermatitis (AD). Egg-
white-specific IgE was detected in 24.3% of patients with AD followed by 
wheat-, milk-, peanut- and soy-specific IgE in order of decreasing frequency.apallergy.org
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Many studies of AD have been conducted over the last 30 years, 
but it is difficult to suggest treatment guidelines because there 
are many unexplained factors and still remarkable differences 
in management practices. The lack of a therapy considered as 
routine by all practitioners is the major problem in overcoming the 
disinformation that abounds in the lay press and among health 
professionals. 
This ADO guideline was written with the concept of AD as 1) a 
multifactorial inflammatory disease, 2) one of the most common 
chronic childhood diseases predominantly found in infants and 
young children, 3) a disease that tends to wax and wane over 
time, and 4) a disease that disappears with increasing age and/or 
progresses to BA or AR.
Corticosteroid (CS) treatment is essential for the early-
intervention management of inflammation, but ways to improve 
its safety and minimize adverse reactions have been introduced 
to relieve the anxiety of patients and their caregivers. Causes and 
treatments of AD vary between individuals, the individualization of 
management is also considered. 
Because the number of patients is too great to be handled 
by doctor’s offices only, a role of the general public, including 
patients, guardians, educators, press and policy makers, is 
necessary. This guideline was devised to communicate in a simple 
way with these groups. What should be considered is that patients 
and their guardians do not properly understand the chronic nature 
of AD and its tendency for frequent relapsing and remitting, and 
may have various levels of awareness of the severity of the disease. 
This can mean that their distrust of and anxiety over treatment 
reduces their compliance. Thus, the guideline includes an 
explanatory section to correct any mistaken beliefs of the general 
public, patients and their families and to satisfy their expectations 
of a therapeutic effect.
Clinical diagnosis
Methods to diagnose AD, such as Hanifin and Rajka’s criteria 
[30], and those to evaluate the severity of symptoms, such as 
SCORAD [31], have been reported and have been widely used 
for research and education. However, “early diagnosis and early 
intervention”, which is a mainstay of the management of allergic 
diseases, is more important for AD management than determining 
whether symptoms meet the diagnostic criteria or how severe 
the symptoms are. Experienced physicians can easily diagnose AD 
because the characteristic symptoms and lesions of AD are unique 
and are common in infants and young children. If the family 
has a history of allergic diseases, AD can be diagnosed from the 
early lesions. However, differential diagnoses such as seborrheic 
dermatitis, contact dermatitis, nummular eczema, psoriasis and 
immunodeficiency should be considered.
Classification of AD lesions
Both symptoms from acute and chronic lesions defined by skin 
desquamation and thickening can coexist in AD. Depending on 
progression of lesions, there are characteristic findings: early and 
progressive lesions.
This classification is useful to determine when early intervention 
will be performed and what kind of therapeutic level should 
be given. Thus, both acute and chronic lesions have early and 
progressive stages, which can be classified as follows: 
• Acute symptom:
  -   Early lesion: scaly, erythematous patches with a poorly 
defined border
  -   Progressive lesion: weeping, excoriation, crusting, and 
infections
• Chronic symptom:
  -   Early lesion: thicker, paler, scaly plaques
  -   Progressive lesion: thickened and hyperlinear skin with 
erythematous, scaling papules and patches
Although it is not easy to distinguish between acute and 
chronic symptoms, one is differentiated from the other by the 
degree of skin thickness observed by inspection and palpation. 
For acute symptom, red and palpable rough skin is considered as 
an early lesion and the association of weeping with more severe 
skin eruptions is regarded as a progressive lesion. For chronic 
symptom, the skin is thicker than in acute symptoms. Early and 
progressive lesions of chronic symptoms are divided by the degree 
of thickness and wrinkles. Chronic symptoms frequently combine 
with acute symptoms.
Characteristic clinical manifestations
Itching is an essential symptom for the diagnosis of AD. The 
distribution of skin lesions is very characteristic. In infants, the face, 
neck, trunk and lateral surface of the extremities are commonly 
affected. As children grow older, the lesions move to or expand to 
the cubital and popliteal fossae, ear lobes, wrists and ankles where  apallergy.org
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the skin is folded. As these symptoms recur, in a typical chronic 
lesion the skin becomes thickened and wrinkled. In the chronic 
stage, complications including infections are more frequent and it 
can produce very severe acute symptoms. 
Composition of the ADO guideline
Because AD is an inflammatory disease, using anti-inflammatory 
drugs is the cornerstone of treatment. In particular, CSs have been 
widely used as one of the strongest and most effective types 
of anti-inflammatory drugs. However, they can cause adverse 
reactions such as inhibition of growth of children and a rebound 
phenomenon, which lead to anxiety for patients and their 
caregivers.
This ADO guideline refers to the treatment steps of PRACTALL, 
which are based on CS preparation. While PRACTALL classifies the 
treatment stages by severity of disease [13], this ADO guideline 
classifies them by acute and chronic symptoms and by early and 
progressive lesions.
The basic framework of the ADO guideline consists of three 
steps (Fig. 5). Step 1 management is basic management for all 
cases of AD. It consists of skin care, dietary management, indoor 
environmental control and psychological support. Just carrying 
out this step faithfully can decrease the deterioration of symptoms 
and the use of CS drugs. Step 2 therapy is an add-on therapy to 
treat skin inflammation and itching of acute lesions that do not 
improve with step 1 management. Topical CS (TCS) therapy is the 
major therapeutic agent in step 2 therapy, and topical calcineurin 
inhibitor (TCI) can also be used for children over two years of age. 
Antihistamines for itching and antibiotics for skin infection are 
also included. Step 3 therapy is systemic administration of CS in 
cases not improved by steps 1 and 2 therapy. Immunosuppressive 
treatments such as cyclosporin A, azathioprine, immunotherapy, 
intravenous immunoglobulin, ultraviolet (UV) light therapy and 
unverified treatments such as herbal medicines may also be 
included in step 3 therapy.
Step 1 Management: skin care, dietary management, indoor 
environmental control and psychological support 
This step is the basic and essential management for all stages of 
AD. It consists of proper skin care, dietary management, and indoor 
environmental control without medication. In addition, it includes 
psychological support and education of the parents. If conducted 
thoroughly, it is very effective for treating the early lesions of acute 
and chronic symptom and is the best way to reduce the use of 
medicines and the exacerbation of acute symptoms and to induce 
resolution of the disease at an early age.
Skin management
Basic skin care is essential for AD management. AD patients 
have characteristically dry skin following the loss of water in the 
skin because of skin damage. Various exacerbating factors trigger 
pruritic skin inflammation, which often leads to a vicious cycle 
of scratching followed by further itching. This damaged skin is 
vulnerable to infections with bacteria, fungi, viruses and scabies. 
The skin of AD patients is mostly colonized by S. aureus, a toxin-
producing organism. Therefore, proper skin care consists of skin 
Fig. 5. Basic framework of the stepwise management in the Atopic Dermatitis Organizer (ADO) guideline. The contents of this ADO guideline basically consist of 
3 steps approaches: conservative management, topical anti-inflammatory therapy, and systemic anti-inflammatory therapy. IVIG: intravenous immunoglobulin.apallergy.org
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hygiene, moisturizing and avoidance of irritants.
Regular showers and tub bathing: For skin hygiene and 
hydration, regular showers and tub bathing are essential. Although 
soap can be used for skin hygiene, it can produce skin damage. For 
decreasing skin damage, neutral or weakly acidic pH soaps have 
been recommended. However, it should be rinsed off thoroughly 
with clean water after bathing. 
Moisturizers: Emollient should be applied regularly. The roles of 
ideal moisturizers are as follows: 1) to improve skin dryness [32], 
2) to maximize treatment effects of TCS [33], 3) to decrease the 
amount of TCS required [34], and 4) to reduce chances of infection 
by recovering disrupted skin barrier [35]. 
Avoidance of irritants: Irritation is also an aggravating factor for 
AD. Patients with AD are recommended not to wear too tight or 
loose clothing, and not to use fabrics producing static electricity 
[36]. 
Dietary management
Because AD frequently occurs at ages involving a growth 
spurt, nutrients for growth must be supplied. Therefore, dietary 
restriction should be applied carefully, and if a food must be 
avoided, appropriate diets that will not hamper normal growth 
should be prepared by choosing a substitute food. As the 
possibility for food to be a trigger of AD is higher at younger ages, 
food management at this age is critical for AD management. 
Dietary management is classified into food avoidance and 
preparation of a diet for proper nutrient supply.
Food avoidance: Because the results of a laboratory test are not 
always consistent with symptoms, food cannot be restricted based 
only on the result of a laboratory test. Food diary and challenge 
test are necessary for the confirmations. When food challenge is 
conducted, careful attention should be paid to the possibility of 
anaphylaxis in patients with urticaria or angioedema rather than 
AD.
For the prevention of AD, breastfeeding is commonly 
recommended. However, it should be considered that the 
maternal diet can produce symptoms of AD. Probiotics are 
sometimes recommended in high-risk infants [37].
Nutrient management: When a food that is confirmed to 
be associated with AD is avoided, food substitution should be 
provided. The cooking method is also considered. For example, 
raw rice shows an allergenic band in immunoblotting but the 
band disappears after boiling [38]. Cooking methods such as 
roasting were reported to enhance allergenicity [39]. 
Indoor environmental management
Studies in Korea and other countries have reported that 
residential environmental pollution is a factor in the development 
of symptoms of AD [2, 40-44]. Our clinical study on the therapeutic 
effect of a low-pollutant (PM10, formaldehyde, bacterial and 
mold suspension) ward also revealed that improvement of the 
environment had a positive effect. The duration of treatment was 
reduced and the pollutant levels were measured to be higher at 
the patient’s home than in the wards. Children spend over 20 h a 
day in indoor environments including childcare facilities, daycare 
centers, kindergartens, schools and private educational institutions, 
so reducing pollution in the indoor environment is important for 
AD management.
Ventilation: Ventilation is the first step to reduce indoor 
pollution. Pollutants from new furniture, furnishing materials 
including wallpaper, air-conditioning and heating equipment and 
cooking utensils should be decreased by ventilation. New interiors 
or new furniture need more frequent ventilation. An air cleaner is 
also helpful but a habit of frequent ventilation is more effective 
and reliable.
Cleaning: Fungi and bacteria can be factors in worsening 
symptoms of AD and can provoke more severe symptoms in skin 
lesions with infection. Cleaning is the best way to decrease fungi 
and bacteria in the indoor environment [45, 46].
Adequate humidity: Maintaining adequate humidity is effective 
in reducing the deterioration of lesions by preventing dry skin. 
However, excessive humidity can promote the propagation of 
HDM, fungi and bacteria, so it is appropriate to maintain around 
50% humidity.
Psychological management
The most common problem in severely affected AD children is 
exhaustion from not sleeping well, leading to poor concentration 
at school [47]. Dietary restriction and anxiety can negatively affect 
the development of confidence, autonomy and personal initiative. 
In most cases of moderate to severe AD, counseling is required to 
help overcome the emotional burdens associated with the disease 
itself and the fears that most parents have about treatment, such 
as steroid phobia. 
Step 2 Management: first stage of pharmacological interven-
tion
Step 2 therapy should be added for acute symptoms of AD if the  apallergy.org
Lee SI, et al.
Asia Pacific
allergy
doi: 10.5415/apallergy.2011.1.2.53 60
skin lesion is not improved by step 1 management. The targets of 
step 2 therapy are to break out of the vicious cycle of disease and 
to treat skin inflammation.
 Antipruritic medications
Antihistamines are widely used for the management of 
pruritus. Antihistamines are generally divided into six groups. 
Depending on their action time and sedative properties, each 
group is classified into first- and second-generation drugs. When 
tachyphylaxis occurs, an antihistamine from another group can 
be used. Sedating first-generation antihistamines are still more 
useful in AD than the nonsedating antihistamines [48], but their 
use in children is often reserved for nighttime dosing to minimize 
drowsiness and lack of concentration during the daytime [49].
Treatment of skin infection
Disruption of the skin barrier and a deficiency in the expression 
of antimicrobial peptides may account for the susceptibility of AD 
patients to various skin infections by bacteria, fungi and viruses 
[26, 27, 50-52]. Heavy colonization of AD patients’ skin with                           
S. aureus is well documented [24]. 
Skin infection is a major factor in aggravating symptoms of AD. 
Suspected skin infection is hard to differentiate from progressive 
lesions in many cases. Generally, an infected lesion tends to have a 
well-defined margin compared with early lesions that have poorly 
defined margins.
For bacterial infection, systemic antibiotics are preferred rather 
than topical agents. Generally, a first- or second-generation 
cephalosporin for 7-10 days is recommended. In case of infections 
with viruses, fungi or scabies, it is better to use individualized 
therapy. If there is no therapeutic effect, skin culture for 
microorganisms should be performed.
Treatment of skin inflammation
For early and progressive lesions of acute symptom not 
improving with step 1 management, topical anti-inflammatory 
therapy should be applied. Although TCS is most widely used, 
many patients and their guardians are reluctant to use it because 
of anxiety over possible adverse effects. Education about safe 
use of TCS to minimize adverse reactions and the rebound 
phenomenon is necessary. TCI can also be safely used for skin 
inflammation.
TCSs: TCSs have been the mainstay of treatment of inflammation 
and are usually divided into grades 1-4 by their strength: mild, 
moderate, strong and very strong ointments, respectively. The 
therapeutic effect of TCSs is obvious for early and progressive 
lesions of acute symptom. While TCSs of grades 1-2 are known to 
have a very low risk of adverse effects, the safest method of drug 
administration should be considered. For application of TCS in the 
early stages of acute symptoms, a morning dose and stepwise 
dose reduction and discontinuance have been suggested and 
used [53]. It is also important to use the appropriate amount of 
TCS. The “fingertip unit” is helpful for this purpose [54]. Although 
disease in most patients can be controlled by TCS, the following 
should be considered if the patient does not show improvement. 
Was step 1 management performed thoroughly? Are the type 
and dosage of medications appropriate? Is there an associated 
complication such as infection? Is lichenification progressing? Is 
the lesion from another disease?
TCIs: The TCIs are steroid-free therapeutic agents used effectively 
and safely to treat the inflammation of AD. Pimecrolimus (Elidel®; 
Novartis, Switzerland) and tacrolimus (Protopic®; Astellas, USA) have 
shown immunomodulatory effects in AD [55]. Both pimecrolimus 
cream (1%) and tacrolimus ointment (0.03%) have been approved 
in the USA, Europe, and Korea for use in children older than two 
years [56]. The most common side effect of TCIs is a transient 
burning sensation of the skin. TCIs can be used as an alternative 
for treatment of sensitive skin areas such as the face and intertrigo 
because they have a low tendency to cause skin atrophy [57]. 
Wet dressing and wet wrap therapy
For the progressive lesion of acute symptom, the wet dressing 
is commonly recommended. Leung developed an advanced type 
of wet dressing, wet wrap therapy [58]. It is very helpful to reduce 
pruritus and inflammation by cooling the skin and to improve 
the penetration of TCS. The wrappings also act as a temporary 
protective barrier from the trauma associated with scratching.  
Therapeutic agents for chronic symptoms
The thickened skin in chronic AD lesions decreases the 
absorption of TCSs and moisturizers, making treatment difficult. In 
this case, adjuvant application of topical keratolytic agents can be 
used, taking care not to allow the agents into the eyes.
Step 3 Management: systemic administration of CS medica-
tions, other immunomodulatory therapies and investigational 
therapeutic regimens
Step 3 therapy should be applied when there is no improvement apallergy.org
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even after following step 1 and step 2 managements. Oral or 
intravenous administration of CS is classified as step 3 therapy. 
Cyclosporin A, interferon gamma injection and UV therapies 
are also included in this stage. Other investigational treatments 
such as omalizumab, intravenous immunoglobulin and herbal 
medicines may also be included.
Most patients with severe symptoms improve clinically with 
rigorous performance of step 1 and step 2 managements, so step 
3 therapy should be considered very carefully. Investigational 
treatments may be moved into step 2 after stringent verification to 
generalize their effects.
CONCLUSION
As is the process for the treatment of other chronic diseases, the 
goal of AD management should be established (Fig. 6). In infants, 
the treatment goal is to reduce the usually severe symptoms of 
AD occurring in this period. In children 2-3 years old, AD tends to 
improve naturally and this improvement can be expected. In the 
preschool period, efforts to prevent other allergic diseases should 
be made because 60-70% of the cases of BA and AR develop 
before five years of age [59]. 
The ultimate goals of this guideline are to decrease the incidence 
of not only AD but also BA and AR in community, to decrease the 
suffering of patients and their guardians and to induce a natural 
outgrow of AD.
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